Transforming growth factor-β (TGF-β) modulates diverse cell physiological processes and plays a complicated role in tumor development. It has been well established that TGF-β inhibits cell proliferation in normal and early stage carcinoma and facilitates tumor metastasis in late-stage carcinoma. Therefore, blocking TGF-β signaling in advanced stage carcinogenesis provides a potentially interesting chemotherapeutic strategy. We aimed to determine the effect of tolfenamic acid (TA) on TGF-β-induced protumorigenic activity. Here, we demonstrate that TA attenuates tumor-promoting effects of TGF-β in cancer cells. Further observation indicates TA blocks the TGF-β/Smad pathway, and this blockage is mainly attributed to the interference of TGF-β1-driven phosphorylation of Smad2/3. We also show that TA could exert this effect on cancer cell lines from several different origins and that TA is much better than other non-steroidal anti-inflammatory drugs with respect to inhibition of TGF-β1-induced Smad2 phosphorylation. Finally, extracellular signalregulated kinase mitogen-activated protein kinase plays a role in TA-induced suppression of Smad2/3 phosphorylation and subsequent nuclear accumulation of Smad2/3 in response to TGF-β1. Our study provides a possible mechanism by which TA affects anticancer activity by inhibiting the TGF-β pathway and sheds light on the application of TA for cancer patients.
Introduction
Transforming growth factor-β1 (TGF-β1), a 25 kDa autocrine/paracrine growth regulator belonging to the large TGF-β superfamily, plays a vital role in the regulation of a wide variety of physiological processes from development to pathogenesis. In the canonical pathway, active TGF-β1 binds to cell surface receptor kinases TGF-β type I (TβRI) and type II receptors (TβRII) (1) . By binding with TGF-β1, TβRII phosphorylates and activates TβRI, which further propagates the signals to the family of intracellular mediators known as Smads (2) . Regulatory Smads (R-Smads) act as direct substrates of TβRI, which phosphorylate R-Smads at the carboxyl terminus within a highly conserved SSXS motif (3) (4) (5) (6) . Of the R-Smads, Smad2 and Smad3 (shortened as Smad2/3) are transduced by activin and TGF-β signaling, whereas Smad1, Smad5 and Smad8 are transduced by bone morphogenetic proteins/growth differentiation factor signaling in most cells, even though TGF-β also induces Smad1/5 phosphorylation in the presence of an accessory receptor in a few other cell types (7, 8) . Once phosphorylated, R-Smads form a complex with the common mediator Smad4 and then shuttle to the nucleus where they activate specific genes through cooperative interaction with DNA and other transcription factors, transcriptional coactivators and/or corepressors (9) (10) (11) (12) .
TGF-β in cancer development may function as a tumor suppressor or tumor promoter, depending on the stage of tumorigenesis. In normal or preneoplastic epithelial cells, TGF-β could inhibit cell growth by inducing cell cycle arrest and apoptosis. Paradoxically, as tumors evolve, they exploit the capabilities of TGF-β for cell invasion, immune regulation and microenvironment modification, thus promoting tumor growth and metastasis (13) . Since overexpression of TGF-β causes a tumor promotion effect in a variety of late-stage carcinomas, antagonizing the TGF-β pathway has shed light on its therapeutic potential in the past several years (14, 15) . Consistently, evidence shows that small-molecule inhibitors of TβRI attenuate the tumor-promoting effect of TGF-β, including inhibition of the TGF-β-induced epithelial-mesenchymal transition (EMT), cell migration and invasion (16, 17) .
Non-steroidal anti-inflammatory drugs (NSAIDs) have been long studied as chemopreventive agents in different cancer types. Extensive epidemiological investigations have proved that long-term use of NSAIDs is associated with significant reduction in the risk of colorectal cancer. Among NSAIDs, tolfenamic acid (TA) is a traditional NSAID that has been broadly used for treatment of migraines with much fewer upper gastrointestinal side effects than other conventional NSAIDs (18) . In recent years, TA has been shown to inhibit cancer growth, which seems associated with the decreased expression of vascular endothelial growth factor and vascular endothelial growth factor receptor 1 in a pancreatic cancer model (19, 20) . Subsequently, several studies indicate TA suppresses tumorigenesis through decreasing oncogenic proteins, such as Sp1 and erbB2, in different cancer types in a cyclooxygenase-independent manner (21) (22) (23) (24) . Previous reports from our group also showed TA induces apoptosis partially via upregulating proapoptotic proteins, such as early growth response-1, NSAID-activated gene-1 (NAG-1) and activating transcriptional factor 3 (ATF3) (25) (26) (27) . Thus, TA could target multiple signaling pathway(s) for its antitumorigenic activity, which remains unclear.
In the present study, we examine the effect of TA on the TGF-β/ Smad signaling pathway in several cancer cells. We have shown that TA blocks TGF-β-induced E-cadherin downregulation, which has been considered as a marker of EMT, and abrogates TGF-β-induced cancer cell migration. Furthermore, TA inhibits TGF-β/Smad signals through suppressing R-Smad phosphorylation and subsequently nuclear translocation induced by TGF-β1. Finally, extracellular signal-regulated kinase (Erk) mitogen-activated protein (MAP) kinase plays a role in TA-induced disruption of the canonical TGF-β signaling pathway. Our data provide novel evidence for understanding the comprehensive mechanisms by which TA exerts potential anticancer activity.
Materials and methods

Reagents and antibodies
TA and SC-560 were purchased from Cayman Chemical (Ann Arbor, MI), and 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl)phenyl-2(5H)-furanone was described previously (28) . Other NSAIDs were purchased from Sigma-Aldrich (St Louis, MO). U0126 and PD98059 were purchased from Calbiochem (San Diego, CA). Recombinant human TGF-β1, control siRNA, ERK1 siRNA, ERK2 siRNA, antibodies for phospho-Smad2 (Ser465/467), Smad2, phospho-Smad3 (Ser423/425), Smad3, phospho-Erk1/2 (Thr202/ Tyr204), Erk1/2, tubulin α/β, poly (ADP ribose) polymerase and E-cadherin were obtained from Cell Signaling Technology (Beverly, MA). Antibody for actin conjugated with horseradish peroxidase was purchased from Santa Abbreviations: DMSO, dimethyl sulfoxide; EMT, epithelial-mesenchymal transition; Erk, extracellular signal-regulated kinase; MAP kinase, mitogenactivated protein kinase; MMP, matrix metalloproteinase; NSAID, non-steroidal anti-inflammatory drug; PAI-1, plasminogen activator inhibitor 1; PBS, phosphate-buffered saline; R-Smads, regulatory Smads; Sp, specificity protein; TA, tolfenamic acid; TBST, Tris-buffered saline containing 0.1% Tween 20; TGF-β, transforming growth factor-β; TβR, TGF-β receptor.
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Cruz Biotechnology (Santa Cruz, CA). All other chemicals were from Fisher Scientific (Pittsburgh, PA), unless otherwise specified.
Cell culture and treatment
Human cancer cell lines (SW480, A549, PC-3 and BxPC-1) were purchased from American Type Culture Collection (Manassas, VA) and cultured in RPMI-1640 media (Mediatech, Herndon, VA) supplemented with 10% fetal bovine serum, 100 U/ml penicillin and 100 mg/ml streptomycin. All cells were grown in a 5% CO 2 atmosphere at 37°C. All treatments were performed in media containing 0.2% fetal bovine serum, and 10 ng/ml TGF-β1 was used in all experiments.
RNA isolation and real-time PCR Total RNAs were isolated by E.Z.N.A. Total RNA Kit (Omega Bio-Tek, Norcross, GA) according to the manufacturer's protocol. RNA (1 µg) was reverse transcribed using a Verso cDNA synthesis kit (Thermo Scientific, Waltham, MA) according to the manufacturer's protocol. Reverse transcription-PCR was performed for analyzing Snail and E-cadherin gene expression. ABsolute qPCR SYBR Green Mix (Thermo Scientific) was used for real-time qPCR to determine PAI-1, MMP2 and MMP9 gene expression. The primer sequences of human genes used were as follows-plasminogen activator inhibitor 1 (PAI-1): forward 5′-CACGAGTCTTTCAGACCAAGAG-3′ and reverse 5′-CACACAAAAGCTCCTGTAAGC-3′; matrix metalloproteinase-2 (MMP2): forward 5′-TTCCCCTTCTTGTTCAATGG-3′ and reverse 5′-ATTTGTTGCCCAGGAAAGTG-3′; MMP9: forward 5′-GCTCTTCCCTGGAGACCTG-3′ and reverse 5′-ACACGCGAGTGAAG GTGAG-3′; Snail: forward 5′-TTCTCACTGCCATGGAATTCC-3′ and reverse 5′-GCAGAGGACACAGAACCAGAAA-3′; E-cadherin: forward 5′-GGCTCAAGCTATCCTTGCAC-3′ and reverse 5′-CTTGAGCCCCAGA GTTTGAG-3′; and glyceraldehyde-3-phosphate dehydrogenase: forward 5′-GGGCTGCTTTTAACTCTGGT-3′ and reverse 5′-TGGCAGGTTTT TCTAGACGG-3′. Gene expression level was analyzed by MyiQ thermal cycler (Bio-Rad, Hercules, CA). All values were normalized by glyceraldehyde-3-phosphate dehydrogenase expression and represented as mean ± SD.
Western blot analysis
Cells were harvested into RIPA buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM ethylenediaminetetraacetic acid, 1% Triton X-100, 1% sodium deoxycholate and 0.1% sodium dodecyl sulfate) with a 1% protease inhibitor mixture (EMD Biosciences, La Jolla, CA) and phosphatase inhibitor (1 mM Na 3 VO 4 and 1 mM NaF). After protein concentration was determined by the BCA protein assay (Pierce, Rockford, IL) using bovine serum albumin as a standard, equal amounts of total proteins (30 μg) were mixed with 2× Laemmli's SDSSample Buffer (Boston Bioproducts, Ashland, MA) and boiled for 5 min. After electrophoresis, proteins were transferred to nitrocellulose membranes (Pall Life Sciences, Pensacola, FL), which were subsequently blocked with Trisbuffered saline containing 0.1% Tween 20 (TBST) and 5% non-fat milk for 1 h at room temperature. Then, the membranes were incubated with primary antibodies diluted with TBST-non-fat milk (1:1000) at 4°C overnight. After three washes with TBST, the membranes were incubated with peroxidase-conjugated immunoglobulin G in TBST-non-fat milk (1:5000) for 1 h at room temperature and then washed with TBST three times for 10 min each. The immunoblots were viewed by enhanced chemiluminescence (Thermo Scientific, Rockford, IL) and quantified by Scion Image Software (Scion, Frederick, MD).
Fractionation of nuclear and cytoplasmic proteins
Cells were pretreated with TA for 6 h and then treated with TGF-β1 for 1 h as indicated in Figures 3 and 6. Fractionation of nuclear and cytoplasmic proteins was performed with the Nuclear Extract Kit following the manufacturer's instructions (Active Motif, Carlsbad, CA). Proteins (30 μg) for each fraction were subjected to western blot analysis.
Immunofluorescence
Cells were plated on a Glass Bottom Culture Dish (MatTek Corporation, Ashland, MA) at a density of 0.3 × 10 6 cells/dish. After proper treatment, cells were washed twice with phosphate-buffered saline (PBS) and fixed with 4% paraformaldehyde for 15 min. After two PBS washes, cells were permeabilized with PBS containing 0.25% Triton X-100 for 10 min, followed by incubating with 1% bovine serum albumin in PBS with Tween 20 for 30 min to block non-specific binding of the antibodies. The cells were incubated with diluted primary antibody for 3 h and with Alexa Fluor-conjugated secondary antibody (Invitrogen, Grand Island, NY) for 1 h in the dark. After counterstaining with 0.5 mg/ml 4′,6-diamidino-2-phenylindole, fluorescence was examined by confocal laser scanning microscopy (Nikon, Melville, NY).
Transient transfection and luciferase assay
Cells were seeded on a 12-well plate at a density of 1.0 × 10 5 cells/well. TGF-β-inducible reporter construct (p3TP-Lux) and PAI-1 promoter luciferase construct (pPAI-800) (generously provided by Dr Yuji Mishina, University of Michigan, Ann Arbor, MI) were each cotransfected with pRL-null vector using PolyJet transfection reagent (SignaGen, Ijamsville, MD) according to the manufacturer's instruction. After 24 h transfection, cells were serum starved overnight and pretreated with dimethyl sulfoxide (DMSO) and TA for 6 h, followed by incubating with TGF-β1 for 18 h. Cells were harvested in 1× Passive Lysis Buffer (Promega, Madison, WI), and activity was examined using a DualGlo Luciferase Assay Kit (Promega). Data were normalized by pRL-null luciferase activity.
RNA interference A549 cells were seeded on a 6-well plate at a density of 0.3 × 10 6 cells/well. After 24 h, control siRNA and combined ERK1 and ERK2 siRNAs were transfected at a final concentration of 100 nM using PepMute siRNA & DNA Transfection Reagent (SignaGen) according to the manufacturer's instruction. After 48 h transfection, cells were treated with TA (50 μM) for 6 h, followed by adding TGF-β1 for 1 h, as indicated.
Wound healing and cell migration assay
For the wound-closure experiment, A549 cells were plated onto a 6-well plate and cultured to confluence. Cells were serum starved for 24 h and then scraped with a yellow tip. Then, cells were treated with DMSO and TA for 6 h, followed by coincubating with TGF-β1 for 30 h. For cell migration, a transwell assay was performed in 24-well polycarbonate membrane inserts with 8.0 μM pore size (Corning Incorporated, Corning, NY). A549 cells (2.0 × 10 4 cells/ well) were plated in the upper chamber using complete media. After 24 h, cells were pretreated with DMSO and TA for 6 h, followed by TGF-β1 incubation for 18 h. Cells in the upper compartment were removed with a cotton swab. Migrated cells were fixed with 4% paraformaldehyde and stained with Crystal Violet. Filters were photographed at ×200 magnification. Migrated cells were expressed as the average number of cells counted from three random fields of view.
Statistical analysis
Statistical analysis was performed with the Student's unpaired t-test. Results were considered statistically significance at *P < 0.05 and **P < 0.01.
Results
TA abrogates TGF-β-mediated promigratory response
To examine the effect of TA on migratory properties of cells responding to TGF-β1, we performed a wound healing assay, in which cells were induced to migrate into the wound area created by scratching confluent cells with pipette tips. As shown in Figure 1A , after TGF-β1 treatment, cells almost completely migrated into the wound compared with cells with no treatment. However, TA-treated cells migrated poorly in response to TGF-β1. We also performed a transwell migration assay, showing that TA blocked promigratory activity in response to TGF-β1 in the epithelial cells ( Figure 1B ). EMT plays a vital role in TGF-β-induced cell migration, in which transcriptional factor Snail and junction component E-cadherin are essential (13) . Thus, we evaluated whether TA could affect the alteration of these genes' expression in response to TGF-β. As a result, TGF-β1 dramatically increased Snail and decreased E-cadherin expression at the messenger RNA level, whereas TA blocked the effect of these two genes' alteration ( Figure 1C) . Moreover, TA dose dependently inhibited TGF-β1-induced E-cadherin decreases, although 50 μM TA alone could slightly downregulate E-cadherin expression ( Figure 1D ). These results suggest that TA could inhibit TGF-β-induced promigratory activity of cancer cells.
TA blocks TGF-β1-induced Smad2/3 transcriptional activity and gene expression
Given the essential role of Smad signaling in TGF-β-induced EMT (29), we further examined whether TA affects the TGF-β/Smad pathway. We employed a TGF-β-inducible reporter construct (p3TP-Lux) containing three consecutive TGF-β response elements and a pPAI-800-Lux containing 800 bp of PAI-1 promoter. These constructs were transfected into A549 cells, and luciferase activity was measured after TGF-β1 and/ or TA treatment. As expected, TA caused a dose-dependent decrease of p3TP-Lux luciferase activity in the presence of TGF-β1 (Figure 2A) . TA also inhibited the PAI-1 promoter activity induced by TGF-β1 ( Figure 2B ). These results demonstrate that TA could inhibit Smad transcriptional activity responding to TGF-β1. Subsequently, expression of TGF-β target genes (PAI-1, MMP2 and MMP9) was examined. As shown in Figure 2C , TA suppressed TGF-β target genes, consistent with the ability of TA to suppress TGF-β-responsive promoters. These data suggest that TA can disrupt the canonical TGF-β pathway in cancer cells.
TA disrupts TGF-β-driven phosphorylation and cellular localization of Smad2/3
To further elucidate the mechanism by which TA suppresses the TGF-β/Smad pathway, we examined TGF-β1-induced C-terminal phosphorylation of Smad2/3 in A549 cells. As shown in Figure 3A , TA treatment for 6 h completely blocked TGF-β1-induced phosphorylation of Smad2/3, whereas total Smad2/3 expression was not changed. Furthermore, we investigated the effect of TA on the TGF-β1-induced cytosol-nucleus shuttle of Smad2/3 in A549 cells. As shown in Figure 3B , TGF-β1 induced nuclear translocation of Smad2/3, which was blocked by TA treatment. TA alone did not affect the localization of Smad2/3. To further determine the effect of TA on subcellular localization of Smad3, A549 cells were treated with TGF-β1 alone or together with TA and analyzed by immunofluorescence using antiSmad3 antibody. Consistent with the western analysis, TGF-β1 treatment dramatically enhanced Smad3 nuclear localization, whereas TA attenuated Smad3 translocation stimulated by TGF-β1 ( Figure 3C ). Therefore, these data indicate that TA-induced disruption of the TGF-β/Smad pathway could be mainly attributed to suppression of R-Smads C-terminal phosphorylation.
TA suppresses TGF-β-induced Smad2/3 phosphorylation in other cancer cells
Since TA has been reported to inhibit tumorigenesis in different cancer types, we wondered whether it could suppress the canonical TGF-β pathway in prostate (PC-3), pancreatic (BxPC-3) and colorectal (SW480) cancer cells. It has been known that these cells express TGF-β receptors and exhibit Smad2/3 phosphorylation responding to TGF-β1 stimulation. As expected, TA also inhibited TGF-β-mediated phosphorylation of Smad2/3 in these cells, suggesting this effect was not cancer-type specific ( Figure 4A-C) . In an attempt to identify other potent NSAIDs that can restrict TGF-β response, we assessed the effect of conventional and cyclooxygenase-2 or cyclooxygenase-1 selective inhibitors on TGF-β1-induced phosphorylation of Smad2/3 in SW480 cells. As shown in Figure 4D , phosphorylation of Smad2 was detected after stimulation with TGF-β1; however, TA was the only NSAID tested that completely suppressed TGF-β1-induced Smad2 phosphorylation. Piroxicam and SC-560 also exhibited some effect on the phosphorylation of Smad2, but much less than that of TA. These results suggest that TA is a potent TGF-β antagonist and could be used for several cancer types.
Erk activation mediates the inhibitory effect of TA on C-terminal phosphorylation and nuclear translocation of Smad2/3
It has been known that MAP kinase activation, including the Erk and JNK pathway, could antagonize TGF-β/Smad signaling (30,31) and we have shown that TA activated the MAP kinase pathway in Pictures were taken after the cell wound (between the lines) was created (top). Then, the cells were treated with DMSO or TA for 6 h, followed by coincubating with TGF-β1 for 30 h (bottom). Representative photos are shown. (B) Transwell migration assay. Cells were plated in the upper chamber using complete media. After 24 h, A549 cells were pretreated with DMSO or TA for 6 h, followed by TGF-β1 incubation for 18 h. Representative photos of migrated cells are shown. The data are represented as mean ± SD of three independent experiments. (C) A549 cells were pretreated with TA for 6 h, followed by incubation with TGF-β1 for 30 h. The expression of snail, E-cadherin and glyceraldehyde-3-phosphate dehydrogenase genes was analyzed by reverse transcription-PCR using specific primers as described in Materials and methods. (D) A549 cells were treated as (C). E-cadherin and actin expression were analyzed by western blot. Data were quantified and normalized, and the relative fold of E-cadherin decrease is labeled. Fig. 2 . TA suppressed TGF-β-induced transcriptional response and gene expression in A549 cells. Cells were transiently transfected in a 12-well plate with 1 μg of DNA including p3TP-Lux (A), pPAI-800-Lux (B) and pRL-null plasmid for 24 h and then treated with TA for 6 h, followed by coincubation with TGF-β1 for 18 h, as indicated. Relative luciferase unit (RLU) was calculated as described in Materials and methods. (C) Cells were treated with TA for 6 h and then coincubated with TGF-β1 for 4 h, as indicated. Total RNAs were isolated and reverse transcribed into complementary DNA. Gene expression was analyzed by real-time PCR as described in Materials and methods. Fold change is represented as the mean ± SD of three replicates, **P < 0.01 versus TGF-β1 only-treated cells. Fig. 3 . TA disrupted TGF-β-driven Smad phosphorylation and nuclear accumulation in A549 cells. (A) Cells were treated with TA for indicated times and then coincubated with TGF-β1 for 1 h. Cell lysates were harvested and then subjected to western blot analysis using C-terminal phosphorylated Smad2 and Smad3, and total Smad2 and Smad3 antibodies. Actin was used as loading control. (B) Cells were treated with TA for 6 h and coincubated with TGF-β1 for 1 h. Cytoplasmic and nuclear proteins were extracted, and western blot analysis was carried out using Smad2 and Smad3 antibodies. Tubulin and poly (ADP ribose) polymerase expression were used as cytoplasm and nucleus markers, respectively. (C) Cells were plated in a glass bottom culture dish for 24 h and treated as (B). Immunofluoresence was performed with Smad3 antibody as described in Materials and methods. 4′,6-Diamidino-2-phenylindole was used to stain nuclei.
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HCT-116 cells (26) . In current studies, we observed that TA induced Erk activation in different cell lines independent of TGF-β signaling ( Figure 5A ). Furthermore, we found that the inhibition of Erk pathway restored TGF-β-driven Smad2 phosphorylation in the presence of TA in SW480 cells ( Figure 5B and Supplementary Figure S1 , available at Carcinogenesis Online). A similar result was obtained in A549 cells (Supplementary Figure S2 , available at Carcinogenesis Online). To further confirm that Erk activation mediated the inhibitory effect of TA on TGF-β1-induced Smad2/3 phosphorylation, we silenced Erk1/2 expression using specific siRNA. As shown in Figure 5C , knockdown of Erk1/2 attenuated the TA-induced decrease in the level of phosphorylated Smad2/3 responding to TGF-β1. However, inhibition of Raf activity did not affect the suppression of Smad2 phosphorylation by TA in the presence of TGF-β1, indicating the MEK/Erk pathway is involved in this process (Supplementary Figure S3 , available at Carcinogenesis Online). Consistently, blockage of MEK1/2 activity using a specific inhibitor increased the nuclear Smad2/3 level in the presence of TA ( Figure 6A ). These findings suggest that TA activates the MEK/Erk pathway, which then attenuates TGF-β1-induced phosphorylation and nuclear translocation of Smad2/3 ( Figure 6B ).
Discussion
TGF-β plays a key role in modulating cell proliferation, differentiation and migration in Smad-dependent and Smad-independent manners (32) . However, the role of TGF-β in tumor development seems to be more complex. The inhibitory effect of TGF-β signaling on normal epithelial and some transformed tumor cells implicates TGF-β as a tumor suppressor, whereas advanced tumor cells benefit from activation of TGF-β/Smad pathways, including EMT, myofibroblast generation and immune invasion, thereby enhancing development of metastasis (13) . Since chemotherapy is often used in clinics for the treatment of cancer patients with highly malignant tumors, in which TGF-β functions as a tumor promoter, blockage of the TGF-β pathway using small molecular compounds has been considered a potential and attractive cancer therapeutic strategy. Previous studies using inhibitors of TβRI kinase have shown that suppression of tumor progression by blocking the TGF-β signaling network may provide an effective therapeutic intervention in the late stage of carcinoma (17, 33) . However, these specific inhibitors could also disrupt the tumor suppressive effect of TGF-β in normal or preneoplastic epithelia, causing unwanted side effects (34). Although we did not observe any effects by TA on TGF-β-induced Smad phosphorylation in HEK293 cells (transformed cells) (Supplementary Figure S4 , available at Carcinogenesis Online), further investigation is required to determine whether prolonged use of TA has clinically adverse effects.
TGF-β1-induced EMT and migration in A549 cells have been well documented (35, 36) . Here, we have demonstrated that TGF-β1 triggers the loss of E-cadherin (a marker for EMT) and cell migration in lung cancer cells, which could be abrogated by TA. However, TA itself resulted in a slight decrease in E-cadherin expression at messenger RNA and protein levels after 36 h, which might be explained by increasing Snail expression ( Figure 1C) . It has been reported that Snail negatively controls E-cadherin expression (37). Thus, it is likely that TA increases Snail expression, thereby decreasing E-cadherin expression at a higher dose. Nevertheless, TGF-β1 did not alter E-cadherin expression in the presence of TA, compared with TA treatment alone. Although a previous study showed TA inhibited lung cancer cell growth and tumor formation (23) , our data further suggest that TA could inhibit TGF-β-driven cancer metastasis. Further observation showed that TA interfered with the TGF-β/Smad pathway through suppressing C-terminal phosphorylation and subsequent nuclear translocation of Smad2/3. To our knowledge, this is the first report to show that TA suppresses the TGF-β/Smad pathway, which provides attractive evidence toward developing new inhibitors of TGF-β signaling in cancer research. More importantly, the interference of Smad2/3 phosphorylation by TA has been observed not only in lung cancer cells but also in different cancer cell lines, including prostate, pancreatic and colorectal cancer. It has been known that TGF-β1 can affect Smad2/3 phosphorylation and nuclear stimulation, although BxPC-3 and SW480 cells lack Smad4 expression (38) . These results provide a novel avenue for the investigation of antitumorigenesis activity of TA.
We screened the inhibitory effect of representative NSAIDs from different classifications on TGF-β-induced phosphorylation of Smad2, because NSAIDs could be classified based on their chemical structure. Surprisingly, TA distinguishably exhibited a better inhibitory effect compared with other NSAIDs ( Figure 4D ). TA has also been reported to have superior activity compared with other NSAIDs in Sp1 downregulation (19) , ATF3 induction (26) and NAG-1 induction (25) . These results support a specific and attractive role of TA in either blocking or preventing tumorigenesis. For recent years, specificity protein (Sp) transcription factors have been extensively identified as direct targets of TA, which in turn regulates several pro-oncogenic factors (19, 20, 22, 23) . We also observed downregulation in Sp1 expression after TA treatment for 24 h in different cell lines (Supplementary Figure S5 , available at Carcinogenesis Online). This result suggests that TA would affect cancer growth through an Sp1-dependent mechanism for a longer treatment (>24 h). However, TA-triggered disruption of the TGF-β/Smad pathway could occur in an Sp-independent manner, since dephosphorylation of Smad2/3 occurred within 6 h in cells tested here.
Crosstalk between the MAP kinase pathway and TGF-β signaling has been extensively reported (39) . We have previously demonstrated that TA activates the MAP kinase pathway in HCT-116 cells (26) . In this study, we have shown that TA activates Erk in TGF-β1 responding cells, resulting in the disruption of TGF-β-driven Smad2/3 phosphorylation and translocation. Erk could be activated by a TGF-β signal, producing a Smad-independent transcriptional response in a set of mesenchymal cells (40) . Thus, TGF-β-activated MAP kinase pathways seem to arise in a receptor kinase-independent manner, requiring a specific cellular mediator that recruits to a different domain of the receptor. This implies that expression profiles of such cellular mediators might elicit quite different cellular responses in response to TGF-β. Consistent with previous reports, our data show that TGF-β1 treatment does not induce phosphorylation of Erk, compared with TA treatment (Figure 5A ), suggesting that TA-induced Erk activation is independent of TGF-β's effect in the cell lines tested. Furthermore, the pattern of Erk activation matched with the suppression of the TGF-β-induced Smad phosphorylation in different cells treated with TA.
We have shown that TA inhibits phosphorylation of Smad2/3 at the C-terminal region and that Erk plays a role in this pathway. It has been reported that the Erk MAP kinase could block Smad2/3 nuclear translocation through directly phosphorylating the linker region of Smad2/3, instead of interfering with its C-terminal phosphorylation (30) . However, in this study, phosphorylation of Smad2/3 was still suppressed even though TA did not activate Erk after 24 h treatment (Figures 4 and 5) , suggesting that Erk activation could regulate the activity of unknown mediator(s) that control Smad2/3 phosphorylation. A possible explanation is that the Erk MAP kinase can phosphorylate TG-interacting factor, one of the corepressors of Smad2/3, leading to TG-interacting factor stabilization (41) . TG-interacting factor can suppress Smad2/3 C-terminal , A549, PC-3 and BxPC-3 cells were treated with TA for indicated times, followed by incubation with TGF-β1 for 1 h. Activation of Erk was analyzed by western blot using phospho-Erk (Thr202/Tyr204). Total Erk expression was used as a control. (B) SW480 cells were treated with PD98059 and U0126 at indicated doses for 1 h and then coincubated with TA for 24 h followed by TGF-β1 for 1 h, as indicated. Smad2/3 C-terminal phosphorylation and Erk phosphorylation were analyzed by western blot. (C) A549 cells were transfected with control siRNA and combined siRNAs against ERK1 and ERK2 for 48 h. After that, cells were treated with TA for 6 h, followed by TGF-β1 for 1 h, as indicated. Cell lysates were subjected to western blot analysis using indicated antibodies.
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phosphorylation through a mechanism independent of association with Smad2/3 (42) . It is also plausible that activation of Erk might modulate activation or expression of a specific protein that competes with Smads for binding to receptors. More precise molecular mechanism(s) by which TA activates Erk and inhibits phosphorylation of R-Smads in response to TGF-β remain elusive and are topics for our current investigation.
Collectively, this study suggests that TA has the potential to be a therapeutic agent in the late stages of human cancers. Due to most colorectal cancer cell lines harboring mutant TβRII and Smad4 (43) , it is difficult to evaluate the effect of TA on TGF-β signaling in vitro. However, one report found no mutations in TβRII and one mutation in Smad4 from 31 adenocarcinoma and 11 adenoma samples (44) , suggesting the TGF-β pathway could still facilitate tumor progression in vivo. Thus, the effect of TA on the canonical TGF-β pathway in mouse models and/or human beings needs to be investigated.
Supplementary material
Supplementary Figures S1-S5 can be found at http://carcin.oxfordjournals.org/ 6 . MEK/Erk pathway is involved in TA-induced disruption of TGF-β1-stimulated Smad2/3 nuclear translocation. (A) A549 cells were treated with U0126 for 1 h, then coincubated with TA for 6 h followed by TGF-β1 for 1 h as indicated. Cytoplasmic and nuclear fractions were obtained as described in Materials and methods. Western blot analysis was performed using indicated antibodies (SE, short exposure; LE, long exposure). (B) The scheme of the mechanism by which TA interfered with the canonical TGF-β signal pathway. TA can activate the MEK-Erk pathway by an unknown mechanism, which blocks C-terminal phosphorylation and subsequent nuclear accumulation of Smad2/3 driven by TGF-β1. The inhibitors of MEK, PD98059 and U0126 could partially restore the effect of TGF-β1 in the presence of TA.
